Royalty Pharma plc Class A Ordinary Shares (RPRX) Stock Price, Quote & AI Analysis

Live RPRX stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Royalty Pharma plc Class A Ordinary Shares.

TradeVae provides AI-driven analysis and real-time market intelligence for Royalty Pharma plc Class A Ordinary Shares (RPRX), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.

RPRX
Royalty Pharma plc Class A Ordinary Shares
real-time
$0.00 +0.00 (+0.00%)
Open
41.520000
High
42.005000
Low
41.460000
Volume
1,593,837
VWAP
-
Market Cap
$17,265,071,030.49
52W Range
$29.66 - $42.01
P/E Ratio
-
EPS
-
Dividend Yield
211.13%
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
Feb 11, 2026 Q4
After Hours
EPS Estimate: $1.3289
Revenue Estimate: $804,196,560.00
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Royalty Pharma plc Class A Ordinary Shares's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Royalty Pharma plc Class A Ordinary Shares Overview

Company information

Company Overview

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Company Details
Market Cap
$24.25B
Shares Outstanding
577,287,502
Weighted Shares Outstanding
427,247,489
CEO
Pablo Gerardo Legorreta
Address
110 EAST 59TH STREET, NEW YORK, NY, 10022
Employees
99
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and signals

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Royalty Pharma plc Class A Ordinary Shares Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...